← back to search

Huiran Zhang

Hebei Medical University · CN
Area of research
Molecular Biology · Cellular and Molecular Neuroscience
Research interest
Research interests include Ion channel regulation and function, Neuroscience and Neuropharmacology Research, Cancer Immunotherapy and Biomarkers, and Lung Cancer Diagnosis and Treatment.
h-index
3
citations
31
works
11
NIH funding
primary concept
email

Recent publications

Neuroprotective Effects, Mechanisms of Action and Therapeutic Potential of the Kv7/KCNQ Channel Opener QO-83 in Ischemic Stroke
Translational Stroke Research 2025cited by 2position: firstdoi
LRRC8A in endothelial cells contributes to the aberrant blood-brain barrier integrity in ischaemic stroke
Stroke and Vascular Neurology 2025cited by 2position: lastdoi
Neuroprotective effects, mechanisms of action and therapeutic potential of the Kv7/KCNQ channel opener QO-83 in ischemic stroke
Research Square 2024cited by 0position: firstdoi
Protective effects of low-intensity pulsed ultrasound (LIPUS) against cerebral ischemic stroke in mice by promoting brain vascular remodeling via the inhibition of ROCK1/p-MLC2 signaling pathway
Cerebral Cortex 2023cited by 14position: middledoi
Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor
ESMO Open 2022cited by 3position: middledoi
Biosynthesis of Novel Naphthoquinone Derivatives in the Commonly-used Chassis Cells Saccharomyces cerevisiae and Escherichia coli
Applied Biochemistry and Microbiology 2021cited by 4position: middledoi
98P Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
Annals of Oncology 2021cited by 2position: middledoi
MA02.06 A Randomized, Double-Blind, Placebo-Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC
Journal of Thoracic Oncology 2018cited by 1position: middledoi
A phase I-II clinical trial to evaluate the safety, pharmacokinetics and efficacy of high dose intravenous ascorbic acid synergy with mEHT in Chinese patients with stage III-IV non-small cell lung cancer
Annals of Oncology 2017cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hailin Zhang · Hebei Medical University3 papers (2024–2025)Chang Liu · Hebei Medical University3 papers (2024–2025)Rong Chen · Nanjing University of Chinese Medicine3 papers (2023–2025)Yanfei Tian · Hebei Medical University3 papers (2024–2025)Xiaona Du · Hebei Medical University3 papers (2024–2025)Yupeng Zhao · The University of Sydney3 papers (2024–2025)Yan Wang · Kanazawa University3 papers (2024–2025)Han Hao · Hebei Medical University2 papers (2024–2025)Jinlong Qi · Hebei Medical University2 papers (2024–2025)Najing Zhou · Hebei Medical University2 papers (2024–2025)Xiangyu Wang · Hebei Medical University2 papers (2024–2025)Yi Yuan · Hebei Medical University2 papers (2024–2025)Lanxin Liu · Shanghai Medical College of Fudan University2 papers (2024–2025)Renhao Xu · Hebei Medical University1 papers (2023–2023)Huaxing Zhang · Hebei Medical University1 papers (2025–2025)Jian Hu · Xijing Hospital1 papers (2021–2021)J. Chen · Guangxi University1 papers (2021–2021)Yunpeng Yang · CSPC Pharmaceutical Group1 papers (2022–2022)Lei Sun · East China University of Science and Technology1 papers (2021–2021)Yini Huang · Zhejiang Chinese Medical University1 papers (2022–2022)